BackgroundThe COVID-19 pandemic presented an unprecedented challenge to identify effective drugs for prevention and treatment.ObjectiveTo characterize acute renal injury (AKI) in patients with COVID-19 and their relation with clinical outcomes within the framework of the SENTAD COVID clinical trial at the Abu Dhabi Stem Cells Center.MethodsAbu Dhabi Stem Cell Center (ADSCC) proposed a prospective clinical trial nebulization treatment with autologous stem cells (Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)), at Abu Dhabi hospitals.Participants20 treated patients were compared with 23 not treated patients. Both groups received COVID 19 standard treatment.OutcomesAfter the results were collected, this study was created to determine the impact of the disease on the renal function and the efficacy of the therapy on patient’s outcomes.ResultsOne third of the critical patients studied suffered kidney failure. Patients in the treated group showed a favorable tendency to improve in contrast to those in the control group. Less patients from group A suffered from sepsis in comparison with the group B (25% vs 65%), HR=0.38, (95% Confidence Interval: 0.16 – 0.86), *p=0.0212. These results suggested a NNT=2.5. An improvement in lymphocyte count, CRP, and shorter hospital stay after treatment was evidenced, which led to less superinfection and sepsis in the treated group.ConclusionsThe proposed anti-inflammatory effect of the stem cells, offers a great promise for managing the illness, emerging as a crucial adjuvant tool in promoting healing and early recovery in severe COVID-19 infections and other supportive treatments.ARTICLE SUMMARYOur study had several strengths and limitation: It was a randomized trial.The treatment showed a positive result, providing evidence that this intervention is effective in routine practice.We found fewer complications related to prolonged hospital stay in the treated group.The is the small number of participants.It was carried out in 4 different hospitals, each with different criteria for the selection of the initial empirical antimicrobials, which can cause multiple resistant germs.

A 41-year-old man with oral pemphigus vulgaris (PV) presented to our clinic with a history of no response to numerous immunosuppressant agents and was referred for extracorporeal photopheresis (ECP) therapy. Although the patient underwent a high-intensity ECP regimen for 5 months, which included two different photopheresis systems, his oral dysesthesia continued to interfere with oral intake, leading to continued weight loss and other adverse events. The intervention was associated with changes in several immune cell subpopulations without modifying the anti-epidermal antibody titers, aligned with his poor clinical outcome. To the best of the authors' knowledge, this is the first report to examine immunophenotyping of a PV patient who was refractory to previous immunosuppression and recalcitrant to high-intensity ECP therapy. | INTRODUC TI ONPemphigus diseases are chronic, autoimmune blistering disorders that can be life-threatening if not properly diagnosed and treated.Autoantibodies directed against desmosomal adhesion proteins, desmoglein (Dsg)-1 and Dsg-3, are critical in its etiopathogenesis.These diseases are diagnosed based on the clinical features as well as IgG and/or complement C3 deposits at the keratinocyte membrane: This is detected by direct immunofluorescence microscopy and a perilesional biopsy, with serum anti-Dsg-1 or anti-Dsg-3 antibodies. 1 The most common forms are pemphigus vulgaris (PV), which often arises with mucosal involvement, and pemphigus foliaceus, characterized by predominant skin lesions. 1 Pemphigus treatments include corticosteroids and several immunosuppressant agents, but some patients, especially those with severe variants, are still refractory to them. In these cases, rational approaches such as therapeutic plasma exchange (TPE), immunoadsorption, or extracorporeal photopheresis (ECP) have low-quality supporting evidence and weak strength in grading recommendations. 2,3

Evaluation of immunoprofile as predictive and prognostic biomarker are essential to follow up patients in Multiple Myeloma after autologous hematopoietic stem cells transplantation (AHSCT). It can be defining the engraftment and predicts complications. An AHSCT was performed for the first time in the United Arab Emirates to treat a patient with multiple myeloma. We apply the evaluation of the patient's immune status before and during the early follow-up by flow and mass cytometry. The analysis revealed a decrease in all leukocyte populations in blood seven days after transplantation, mainly of B and T helper lymphocytes. The patients showed diarrhea and cellulitis as complications. An increase in regulatory T and NK lymphocytes was evidenced at the same time. 28 days’ post-transplantation, all lymphocyte populations were recovered, except for B lymphocytes, a high level of T regulatory and NK was maintained. The early immune restoration coincided with the recovery of the complications presented by the patient. the leukocyte composition of apheresis was similar to that found in blood at baseline time. Our study evidenced that the extended immunoprofile by mass cytometry could be useful to predict the outcome and response to transplantation.